Company intelligence / Profile preview

Sequential Medicine Ltd.

Ownership: Private
Development stage: Phase 2

Overview

SM-1, their lead product for transient insomnia, has shown significant improvement in total sleep time compared to placebo in clinical trials, with no evidence of next-day impairment. The drug was well-tolerated with adverse events comparable to placebo.

Therapeutic areas: Psychiatry
Modalities: Combination therapiesSmall molecules
Industry: Biotech

Drug pipeline

1 asset

SM-1

Phase 2

Indications: Transient insomnia

Partnerships

Tedor Pharma (manufacturing)

Beyond the preview

Go deeper on Sequential Medicine Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequential Medicine Ltd..

Explore the full profile